



Hikma receives FDA approval for Acyclovir Injection

London, 9 March 2016 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its abbreviated new drug application (“ANDA”) for Acyclovir Injection USP, 500mg/vial and 1 gm/vial, single dose vials, has been approved by the U.S. Food and Drug Administration (“FDA”).

Acyclovir Injection is used to treat initial and recurrent herpes simplex, shingles (varicella zoster) infection, genital herpes and herpes simplex encephalitis. According to IMS Health, sales of Acyclovir Injection in the US market were approximately \$14.7 million for the 12 months ending January 2016.

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal, VP Corporate Strategy and Investor Relations

+44 (0)20 7399 2760/ +44 7776 477050

Zeena Murad, Investor Relations Manager

+44 (0) 20 7399 2768/ +44 7771 665277

FTI Consulting

Ben Atwell/ Matthew Cole

+44 (0)20 3727 1000

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa (“MENA”) and Europe. In 2014, Hikma achieved revenues of \$1,489 million and profit attributable to shareholders of \$278 million.